芳香化酶抑制剂治疗期间乳腺癌患者症状群对生活质量的影响

目的 探讨乳腺癌患者在接受芳香化酶抑制剂(aromatase inhibitor,AI)治疗期间所出现的症状群及生活质量,并分析症状群与生活质量的相关性.方法 采取横断面调查,选取2020年4月—2021年1月就诊于北京市某肿瘤专科医院乳腺中心门诊患者260例.采用一般情况调查表、安德森症状量表、简明健康调查量表进行调...

Symptom clusters and the effects on quality of life among breast cancer patients receiving aromatase inhibitors

Objective To investigate the symptom clusters and the quality of life of breast cancer patients receiving aromatase inhibitors（AI） and to analyze the correlation of the symptom clusters and the quality of life. Methods With the adoption of a cross-sectional study,260 breast cancer patients who were undergoing AI treatment in a Beijing Cancer Hospital were surveyed from the time range between April 2020 to January 2021. The demographic data,MD Anderson symptom inventory,medical outcomes study 36-items short-form health survey were used for investigation. Results 254 valid questionnaires were collected and analyzed. Through principal component analysis,3 groups of symptom groups were extracted,namely disease symptom cluster,treatment-related-psychological symptom cluster and gastrointestinal symptom cluster. The results showed that the scores of physical component score and mental component score were（38.51 ± 12.03） and （43.06 ± 14.29） respectively. The results of multiple linear regression analysis showed that the more severe the disease symptom cluster,the more severe the treatment-related psychological symptom cluster,the higher the BMI and the lower the education level,the worse physical health will be. With the extension of oral AI,the physical health improved. The more severe the treatment-related psychological symptom cluster,the worse the mental health will be. Conclusion Breast cancer patients receiving AI experienced multiple symptoms clusters. There was a negative correlation between symptom clusters and quality of life. It’s necessary to pay more attention to the patients accepting outpatient AI treatment. Targeted interventions need to develop to relieve symptom clusters and improve the quality of life.